nVerses Capital LLC Makes New Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

nVerses Capital LLC purchased a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 2,500 shares of the biopharmaceutical company’s stock, valued at approximately $50,000.

Several other hedge funds have also recently modified their holdings of CPRX. Arizona State Retirement System lifted its stake in shares of Catalyst Pharmaceuticals by 2.2% during the second quarter. Arizona State Retirement System now owns 29,733 shares of the biopharmaceutical company’s stock worth $461,000 after buying an additional 654 shares during the period. GAMMA Investing LLC raised its stake in Catalyst Pharmaceuticals by 62.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 681 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Catalyst Pharmaceuticals by 6.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 11,116 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 720 shares during the period. XTX Topco Ltd grew its stake in Catalyst Pharmaceuticals by 7.5% during the 2nd quarter. XTX Topco Ltd now owns 11,134 shares of the biopharmaceutical company’s stock valued at $172,000 after purchasing an additional 773 shares during the last quarter. Finally, Strategic Advocates LLC grew its stake in Catalyst Pharmaceuticals by 6.5% during the 2nd quarter. Strategic Advocates LLC now owns 14,142 shares of the biopharmaceutical company’s stock valued at $219,000 after purchasing an additional 864 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on CPRX shares. Citigroup lifted their price objective on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, August 9th. StockNews.com raised shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Truist Financial upped their price target on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, HC Wainwright increased their price target on Catalyst Pharmaceuticals from $26.00 to $30.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $29.50.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX opened at $21.02 on Tuesday. The firm has a fifty day moving average of $20.23 and a 200 day moving average of $17.46. The firm has a market cap of $2.48 billion, a PE ratio of 38.93, a PEG ratio of 3.18 and a beta of 0.76. Catalyst Pharmaceuticals, Inc. has a one year low of $11.89 and a one year high of $21.85.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.13. Catalyst Pharmaceuticals had a return on equity of 27.77% and a net margin of 15.69%. The business had revenue of $122.71 million for the quarter, compared to the consensus estimate of $111.76 million. On average, equities analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.82 EPS for the current fiscal year.

Insider Activity at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the sale, the director now directly owns 348,874 shares in the company, valued at $7,012,367.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 15,000 shares of the business’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the transaction, the director now owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Carmen Jeffrey Del sold 36,058 shares of the firm’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $18.42, for a total value of $664,188.36. Following the completion of the sale, the insider now directly owns 12,369 shares of the company’s stock, valued at $227,836.98. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 201,058 shares of company stock valued at $4,018,188. Corporate insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.